(MedPage Today) — The FDA on Wednesday granted accelerated approval to linvoseltamab (Lynozyfic) for relapsed or refractory multiple myeloma after at least four prior lines of therapy.
A B-cell maturation antigen (BCMA)-directed bispecific antibody…
Source link : https://www.medpagetoday.com/hematologyoncology/myeloma/116373
Author :
Publish date : 2025-07-02 19:50:00
Copyright for syndicated content belongs to the linked Source.
